Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

729469.pdf (9.94 MB)

Document type

Article

Version

Published version

Publication date

2023-01-05

Publication license

cc-by (c) Renau-Mínguez, Chantal et al., 2023
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/198522

Genomic analysis of Mycobacterium brumae sustains its nonpathogenic and immunogenic phenotype

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.3389/fmicb.2022.982679

Abstract

Mycobacterium brumae is a rapid-growing, non-pathogenic Mycobacterium species, originally isolated from environmental and human samples in Barcelona, Spain. Mycobacterium brumae is not pathogenic and it's in vitro phenotype and immunogenic properties have been well characterized. However, the knowledge of its underlying genetic composition is still incomplete. In this study, we first describe the 4 Mb genome of the M. brumae type strain ATCC 51384T assembling PacBio reads, and second, we assess the low intraspecies variability by comparing the type strain with Illumina reads from three additional strains. Mycobacterium brumae genome is composed of a circular chromosome with a high GC content of 69.2% and containing 3,791 CDSs, 97 pseudogenes, one prophage and no CRISPR loci. Mycobacterium brumae has shown no pathogenic potential in in vivo experiments, and our genomic analysis confirms its phylogenetic position with other non-pathogenic and rapid growing mycobacteria. Accordingly, we determined the absence of virulence-related genes, such as ESX-1 locus and most PE/PPE genes, among others. Although the immunogenic potential of M. brumae was proved to be as high as Mycobacterium bovis BCG, the only mycobacteria licensed to treat cancer, the genomic content of M. tuberculosis T cell and B cell antigens in M. brumae genome is considerably lower than those antigens present in M. bovis BCG genome. Overall, this work provides relevant genomic data on one of the species of the mycobacterial genus with high therapeutic potential.

Subject

Immunogenètica, Mycobacterium tuberculosis, Immunoteràpia

Subject (English)

Immunogenetics, Mycobacterium tuberculosis, Immunotheraphy

Citation

Collections

Articles publicats en revistes (Genètica, Microbiologia i Estadística)
Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC))

Citation

RENAU-MÍNGUEZ, Chantal, et al. Genomic analysis of Mycobacterium brumae sustains its nonpathogenic and immunogenic phenotype. Frontiers in Microbiology. 2023. Vol. 13, num. 982679, pags. 1-24. ISSN 1664-302X. [consulted: 10 of August of 2026]. Available at: https://hdl.handle.net/2445/198522

Export metadata

JSON - METS

Share record